OKYO Pharma (LON:OKYO) Stock Price Down 11.1%
OKYO Pharma (LON:OKYO) Stock Price Down 11.1%
OKYO Pharma Limited (LON:OKYO – Get Rating)'s stock price was down 11.1% during mid-day trading on Tuesday . The company traded as low as GBX 2 ($0.02) and last traded at GBX 2 ($0.02). Approximately 417,748 shares traded hands during mid-day trading, an increase of 83% from the average daily volume of 227,957 shares. The stock had previously closed at GBX 2.25 ($0.03).
周二午盘,Okyo Pharma Limited(LON:OKYO-GET Rating)股价下跌11.1%。该公司股价最低跌至2英镑(0.02美元),最新报2英镑(0.02美元)。午盘交易中,约有417,748股股票易手,较日均成交量227,957股增加83%。该股此前收盘价为2.25英镑(0.03美元)。
OKYO Pharma Stock Up 28.4 %
Okyo Pharma股价上涨28.4%
The business's 50 day moving average price is GBX 2.86 and its 200-day moving average price is GBX 2.98. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.17 and a quick ratio of 2.65. The company has a market cap of £39.72 million and a P/E ratio of -5.39.
该业务的50日移动均线价格为2.86英镑,200日移动均线价格为2.98英镑。该公司的债务权益比为1.65,流动比率为3.17,速动比率为2.65。该公司市值为3972万GB,市盈率为-5.39。
About OKYO Pharma
大代制药公司简介
(Get Rating)
(获取评级)
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Okyo Pharma Limited是一家临床前生物制药公司,致力于为英国患有炎症性眼病和眼痛的患者开发治疗药物。其主导产品包括用于治疗干眼病的OK-101。该公司还在开发OK-201,一种牛肾上腺髓质,脂化肽临床前类似物,用于治疗神经性眼痛。
Further Reading
进一步阅读
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
- 机构将Rite Aid的股票跌至谷底
- 这就是为什么你应该避开联邦快递的反弹
- 维京治疗公司股票为何暴涨
- 耐克公司业绩和前景走高
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大代医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Okyo Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。